86 related articles for article (PubMed ID: 15030521)
1. Dealing with a critical national shortage-Approaches to triaging immune globulin supply in pediatric hematology and oncology.
Edington HJ; Sutton KS; Bennett C; Chandrakasan S; Sterner-Allison J; Castellino SM
Pediatr Blood Cancer; 2020 Jul; 67(7):e28260. PubMed ID: 32329568
[No Abstract] [Full Text] [Related]
2. Comparative effectiveness of two intravenous immunoglobulin products in children with Kawasaki disease, a nationwide cohort study.
Kuo NC; Lin CH; Lin MC
Sci Rep; 2023 Oct; 13(1):18629. PubMed ID: 37903825
[TBL] [Abstract][Full Text] [Related]
3. Immediate adverse events to intravenous immunoglobulin in pediatric patients with inborn errors of immunity: A longitudinal study with a pre-infusion protocol.
Antunes TS; Melo KM; Valente CFC; Tavares FS
Hematol Transfus Cell Ther; 2023; 45(2):253-258. PubMed ID: 36114118
[TBL] [Abstract][Full Text] [Related]
4. Enterovirus type 71-immunized chicken egg yolk immunoglobulin has cross antiviral activity against coxsackievirus A16
Gao E; Wu S; Xu Q; Zeng Y; Tan N; He S; Yang Y; Wei J
Exp Ther Med; 2019 Jul; 18(1):332-341. PubMed ID: 31258670
[TBL] [Abstract][Full Text] [Related]
5. Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres.
Bethune C; Herriot R
Clin Med (Lond); 2019 May; 19(3):201-204. PubMed ID: 31092511
[TBL] [Abstract][Full Text] [Related]
6. A Multicentre Study on the Efficacy, Safety and Pharmacokinetics of IqYmune®, a Highly Purified 10% Liquid Intravenous Immunoglobulin, in Patients with Primary Immune Deficiency.
Krivan G; Chernyshova L; Kostyuchenko L; Lange A; Nyul Z; Derfalvi B; Musial J; Bellon A; Kappler M; Sadoun A; Bernatowska E
J Clin Immunol; 2017 Aug; 37(6):539-547. PubMed ID: 28711959
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.
Ng Q; He F; Kwang J
Viruses; 2015 Dec; 7(12):6441-57. PubMed ID: 26670245
[TBL] [Abstract][Full Text] [Related]
8. Payor issues: barriers to optimal management of patients with primary immunodeficiency.
Shapiro RS; Boyle M
J Clin Immunol; 2012 Sep; 32 Suppl 2():S410-4. PubMed ID: 22918575
[TBL] [Abstract][Full Text] [Related]
9. [Administration of intravenous immunoglobulins in neurology. An evidence-based consensus: update 2010].
Stangel M; Gold R
Nervenarzt; 2011 Apr; 82(4):415-6, 418, 420 passim. PubMed ID: 20577707
[TBL] [Abstract][Full Text] [Related]
10. Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.
Piguet D; Tosi C; Lüthi JM; Andresen I; Juge O;
Clin Exp Immunol; 2008 Apr; 152(1):45-9. PubMed ID: 18241226
[TBL] [Abstract][Full Text] [Related]
11. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.
Berger M; Cunningham-Rundles C; Bonilla FA; Melamed I; Bichler J; Zenker O; Ballow M
J Clin Immunol; 2007 Sep; 27(5):503-9. PubMed ID: 17479360
[TBL] [Abstract][Full Text] [Related]
12. Clinical uses of intravenous immunoglobulin.
Jolles S; Sewell WA; Misbah SA
Clin Exp Immunol; 2005 Oct; 142(1):1-11. PubMed ID: 16178850
[No Abstract] [Full Text] [Related]
13. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
14. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of a new intravenous immunoglobulin preparation in primary immunodeficient patients.
Ochs HD; Lee ML; Fischer SH; Kingdon HS; Wedgwood RJ
Clin Ther; 1987; 9(5):512-22. PubMed ID: 3117369
[TBL] [Abstract][Full Text] [Related]
16. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
17. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency.
Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of adverse events when changing intravenous immunoglobulin preparations.
Ameratunga R; Sinclair J; Kolbe J
Clin Exp Immunol; 2004 Apr; 136(1):111-3. PubMed ID: 15030521
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
